New Hydrogen-Producing Cells Show Promise Against Cancer Tumors
- Authors
- Nailin Yang, Shumin Sun, Jiachen Xu, Fei Gong, Huali Lei, Yu Hao, Zifan Pei, Chenya Wang, Qiao Yu, Jihu Nie, Jiang Nan, Caifang Ni, Liang Cheng
- Journal
- Advanced Materials
- Year
- 2025
- DOI
- 10.1002/adma.202414929
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Cancer
- Body System
- Immune System
TL;DR
Scientists developed a new metal-based treatment that boosts the body's immune response against tumors by altering tumor metabolism and enhancing a key immune pathway.
Key Finding
Manganese galvanic cells simultaneously generate hydrogen gas and manganese ions that activate antitumor immunity while suppressing tumor metabolism, and when combined with immune checkpoint blockade therapy, they significantly suppressed both primary and distant tumors in animal models.
Summary
This study investigated manganese galvanic cells—tiny engineered particles that react with water to produce hydrogen gas and manganese ions—as a potential cancer treatment. Researchers found that these particles could activate an immune pathway called cGAS-STING while also disrupting the way cancer cells use glucose for energy, which normally suppresses that immune pathway. When combined with existing immunotherapy drugs, this approach significantly reduced tumors in animal models.
Practical Takeaway
While this research suggests a novel strategy combining hydrogen gas and manganese delivery for cancer immunotherapy, it remains at the early laboratory stage (cell culture and animal models only). No human trials have been conducted, and the practical applicability to hydrogen water consumption is unclear, as this approach uses engineered particles rather than dissolved hydrogen in drinking water.
Abstract
The cGAS-STING pathway is pivotal in initiating antitumor immunity. However, tumor metabolism, particularly glycolysis, negatively regulates the activation of the cGAS-STING pathway. Herein, Mn galvanic cells (MnG) are prepared via liquid-phase exfoliation and in situ galvanic replacement to modulate tumor metabolism, thereby enhancing cGAS-STING activation for bidirectional synergistic H2-immunotherapy. The obtained MnG can be etched by water, enabling efficient and sustained generation of H2 gas and Mn2+. MnG not only activated and amplified the cGAS-STING pathway through the sustained release of Mn2+ but also regulated tumor glucose metabolism to inhibit the expression of three prime repair exonuclease 2 (TREX2), thereby synergistically enhancing the activation of the cGAS-STING pathway. The injection of MnG into tumors resulted in a robust immune response, thereby providing favorable support for antitumor therapy. Consequently, the combination of MnG with immune checkpoint blockade therapy resulted in significant suppression of both primary tumors and distant tumors. Furthermore, the MnG-lipiodol dispersion exhibited remarkable efficacy in combination with transarterial embolization (TAE)-gas-immunotherapy in a rabbit orthotopic liver tumor model. The present study underscores the significance of employing a metal galvanic cell strategy for enhanced immunotherapy, thereby offering a novel approach for rational design of bioactive materials to augment immunotherapeutic effectiveness.